Abstract
Bronchopulmonary dysplasia (BPD) is complication of premature birth characterised by stunted alveolar growth. Caffeine is a candidate for the management of BPD. We set out to assess the impact of caffeine administration on (i) inflammatory mediators, (ii) expression of components of the transforming growth factor (TGF)-β signalling machinery, and (iii) the development of the mouse lung in a hyperoxia-based mouse model of BPD.
Our preliminary data indicate that daily administration of caffeine (25 mg/kg/day) to newborn mice over the first fourteen days of life did not impact the deleterious effects of hyperoxia on lung development, assessed by lung surface area (SA) in mice treated with room air (21% O2) plus vehicle (physiological saline; SA approx. 152 cm2); hyperoxia (85% O2;大约105厘米2); room air plus caffeine (SA approx. 142 cm2); and hyperoxia plus caffeine (SA approx. 102 cm2). SA was assessed by a stereological approach. In contrast, caffeine administration normalized the body mass of caffeine-treated pups, in the background of hyperoxia exposure. Hyperoxia modulated tumour necrosis factor-α, interleukin (IL)-1β, IL-8, and IL-10 levels in the lung, however, concomitant caffeine administration did not impact the effect of hyperoxia on the expression of these inflammatory mediators . In contrast, caffeine administration did impact the expression levels of both bone morphogenetic protein and TGF-β receptors. These data suggest that caffeine administration in the hyperoxia model cannot correct stunted lung development, however, may impact growth factor pathways relevant to lung development.
- Copyright ©the authors 2016